Concepedia

Clare London

CL

22

Publications

847

Citations

18

H-Index

1984

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

MSD (UK) Limited (United Kingdom)

Clare London is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and drug discovery.

Top concepts

Publications per year

1984–2024

22

Publications

22

Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial

Michael Mullen, Xu Yu Jin, Anne H. Child et al. · The Lancet · 2019 · 128 citations · Full text

Analgesic Effects of a Substituted N-Triazole Oxindole (TROX-1), a State-Dependent, Voltage-Gated Calcium Channel 2 Blocker

Catherine Abbadie, Owen B. McManus, Shu-Yu Sun et al. · Journal of Pharmacology and Experimental Therapeutics · 2010 · 97 citations

Discovery of a novel class of benzazepinone Nav1.7 blockers: Potential treatments for neuropathic pain

Scott B. Hoyt, Clare London, David J. Gorin et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 72 citations · Full text

, , +11

Characterization of the Substituted N-Triazole Oxindole TROX-1, a Small-Molecule, State-Dependent Inhibitor of Cav2 Calcium Channels

Andrew M. Swensen, James Herrington, Randal M. Bugianesi et al. · Molecular Pharmacology · 2011 · 66 citations

Characterization of a New Class of Potent Inhibitors of the Voltage-Gated Sodium Channel Nav1.7

Brande S. Williams, John P. Felix, Birgit T. Priest et al. · Biochemistry · 2007 · 57 citations

, , +21

Rows per page

1–5 of 22